Page 21 - EFH223

3. Hernández-Arroyo MJ, Díaz-Madero A, Menacho-Miguel D. Seguridad en el paciente: prescripción de fármacos que prolongan el intervalo QT. Farm Hosp. 2015; 39(5): 227-239.
4. Agencia Europea de Medicamentos (EMA). Directriz E14 de la ICH (ICH Topic E 14). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Step 5. Note for Guidance on the Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04). November 2005 CHMP/ICH/2/04. Disponible en: http://www.qts-interval- prolongation-proarrhythmic-potential-non-antiarrhythmic- drugs-step-5_en.pdf
5. Rubio Álvaro N, Tejedor Prado P, Hidalgo Correas FJ, García Díaz B. Grave prolongación del intervalo QT por venlafaxina. Farm Hosp. 2014; 38(5): 445-450.
6. Food and Drug Administration. International conference harmonization guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Disponible en:
http:// www.fda.gov/downloads/RegulatoryInformation/ Guidances/ ucm129357.pdf
7. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350: 1.013-1.022.
8. Agencia Española del Medicamento y Productos Sanitarios (AEMPS). Centro de información online de medicamentos
de la AEMPS (CIMA). Boletines de la AEMPS [consultado
en marzo de 2020]. Disponible en: https://www.aemps.gob.es/ home.htm
9. Bello A. Cardiotoxicidad inducida por fármacos: síndrome
de QT prolongado con potencial arritmogénico. Repertorio Medicina y Cirugía. 2020 [DOI: doi.org/10.31260/RepertMedCir. v29.n1.2020.865].
10. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017; 6(12) [pii: e007724]
[DOI: 10.1161/JAHA.117.007724].
11. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and arrhythmia of acquired long QT syndrome: a comprehensive review. Sci World J. 2012; 1-8.
12. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings:
a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010; 55: 934-947.
13. Konstantopoulou A, Tsikrikas S, Asvestas D, Korantzopoulos P, Letsas KP. World J Cardiol. 2013; 5: 175-185 [DOI: http://dx.doi. org/10.4330/wjc.v5.i6.175].
14. Kaufman ES. HeartRhythm. 2009; 6: 51S-55S [DOI: http://dx.doi. org/10.1016/j.hrthm.2009.02.009].
15. Khan IA. Long QT syndrome: diagnosis and management.
Am Heart J. 2002; 143(1): 7-14 [DOI: http://dx.doi.org/10.1067/ mhj.2002.120295].
16. Ridruejo Sáez R, Zalba Etayo B, Civeira Murillo E, Montes Castro N, Munárriz Hinojosa J. Síndrome de QT largo adquirido en pacientes ingresados en UCI. Med Intensiva. 2005; 29(7): 379-383.
17. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003; 45: 415-427.
18. Schwartz PJ, Woosley RL. Predicting the unpredictable: drug- induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016; 67(13): 1.639-1.650 [DOI: 10.1016/j. jacc.2015.12.063].
19. Villamañán E, Armada E, Ruano M. Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos? Med Clin (Barc). 2015; 144(6): 269-274.
20. Vlachos K, Georgopoulos S, Efremidis M, Sideris A, Letsas KP. Expert Rev Clin Pharmacol. 2006; 9: 117-127 [DOI: http://dx.doi. org/doi: 10.1586/17512433.2016.1100073].
21. Woosley RL, Heise CW, Gallo T, Woosley RD, Romero KA. Disponible en: https://crediblemeds.org/ndfa-list/, QTFactors List, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. Disponible en: http://www.crediblemeds.org/
22. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs most patients have easily identifiable risk factors. Medicine. 2003; 82: 282-290.
23. Álvarez E, Vieira S, García-Moll X. Citalopram, escitalopram y QT largo: ¿alerta o alarma? Rev Psiquiatr Salud Ment. 2014; 7: 147-150.
24. Agencia Española de Medicamentos y Productos Sanitarios. Disponible en: http://www.aemps.gob.es/informa/ notasInformativas/medicamentosUsoHumano/seguridad/
25. World Health Organization (WHO). WHO Collaborating Centre for Drug Statistics Methodology. ATC index. Disponible en: http://www.whocc.no/atc ddd index/
26. Prado NFV, Turini AE, Bollis GT, Linhares F, Tieppo A, Devens LT, et al. Long QT syndrome. Geriatr Gerontol Aging. 2017; 11(2): 99-102.
27. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003; 114(2): 135-141 [DOI: 10.1016/s0002-9343(02)01455-9] [PMID: 12586234].
28. Ginzo Cañete AD. Intervalo QTc prolongado en pacientes adultos. Rev Virtual Soc Parag Med Int. 2015; 2(2): 9-22.
29. Martins JM, Pires de Figueiredo T, Coelho Costa S, Moreira Reis AM. Medicamentos que podem induzir prolongamento do intervalo QT utilizados por idosos em domicílio. Rev Ciênc Farm Básica Apl. 2015; 36(2): 297-305. ISSN 1808-4532.
30. Christensen L, Turner JR, Peterson GM, Naunton M, Thomas J, Yee KC, et al. Identification of risk of QT prolongation by pharmacists when conducting medication reviews in residential aged care settings: a missed opportunity? J Clin Med. 2019;
8: 1866 [DOI: 10.3390/jcm811186].
31. Rossi M, Marzi F, Natale M, Porceddu A, Tuccori M, Lazzerini PE,
et al. Drug-associated QTc prolongation in geriatric hospitalized patients: a cross-sectional study in internal medicine.
Drugs Real World Outcomes. 2021; 8(3): 325-335 [DOI: 10.1007/ s40801-021-00234-x] [Epub 2021 Apr 8. PMID: 33834380; PMCID: PMC8324728].
32. Schächtele S, Tümena T, Gaßmann KG, Fromm MF, Maas R. Co-prescription of QT interval prolonging drugs: an analysis in a large cohort of geriatric patients. PLoS One. 2016; 11(5): e0155649 [DOI: 10.1371/journal.pone.0155649].
33. Jackobson G, Carmel NN, Lotan D, Kremer A, Justo D. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes. Z Gerontol Geriatr. 2018; 51(1): 41-47. Disponible en: https://doi. org/10.1007/s00391-016-1155-5
en profundidad
Prescripción de medicamentos con riesgo conocido de prolongar el intervalo QT en pacientes polimedicados crónicos mayores de 65 años de un área de salud
el farmacéutico hospitales n.o 223 21